TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

EC-NAPROSYN

NAPROXEN Cyclooxygenase Inhibitors
Immunology Approved 1994-10-14
1
Indication
--
Phase 3 Trials
31
Years on Market

Details

Status
Prescription
First Approved
1994-10-14
Routes
ORAL
Dosage Forms
TABLET, DELAYED RELEASE

Companies

Active Ingredient: NAPROXEN

EC-NAPROSYN Approval History

Loading approval history...

What EC-NAPROSYN Treats

9 indications

EC-NAPROSYN is approved for 9 conditions since its original approval in 1994. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Rheumatoid Arthritis
  • Osteoarthritis
  • Ankylosing Spondylitis
  • Juvenile Idiopathic Arthritis
  • Tendonitis
  • Bursitis
  • Gout
  • Pain
Source: FDA Label

EC-NAPROSYN Boxed Warning

RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS Cardiovascular Thrombotic Events • Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use [ see Warnings and Precautions ( 5.1 ) ]. • Naproxen tablets and naproxen sodium tablets are contraindicated in the setting of coronary artery bypass ...

Drugs Similar to EC-NAPROSYN

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

NAPROSYN
NAPROXEN
9 shared
ATNAHS PHARMA US
Shared indications:
Rheumatoid ArthritisOsteoarthritisAnkylosing Spondylitis +6 more
NAPRELAN
NAPROXEN SODIUM
6 shared
TWI PHARMS
Shared indications:
Rheumatoid ArthritisOsteoarthritisAnkylosing Spondylitis +3 more
CATAFLAM
DICLOFENAC POTASSIUM
4 shared
AMICI PHARMA
Shared indications:
DysmenorrheaPainOsteoarthritis +1 more
DICLOFENAC POTASSIUM
DICLOFENAC POTASSIUM
4 shared
INGENUS PHARMS LLC
Shared indications:
DysmenorrheaPainOsteoarthritis +1 more
NAPROXEN AND ESOMEPRAZOLE MAGNESIUM
ESOMEPRAZOLE MAGNESIUM
4 shared
Dr. Reddy's
Shared indications:
OsteoarthritisRheumatoid ArthritisAnkylosing Spondylitis +1 more
ABRILADA
ADALIMUMAB-AFZB
3 shared
Pfizer
Shared indications:
Rheumatoid ArthritisJuvenile Idiopathic ArthritisAnkylosing Spondylitis
AMJEVITA
ADALIMUMAB-ATTO
3 shared
Amgen
Shared indications:
Rheumatoid ArthritisJuvenile Idiopathic ArthritisAnkylosing Spondylitis
CELEBREX
CELECOXIB
3 shared
GD SEARLE LLC
Shared indications:
OsteoarthritisRheumatoid ArthritisAnkylosing Spondylitis
CORTEF
HYDROCORTISONE
3 shared
PHARMACIA AND UPJOHN
Shared indications:
Rheumatoid ArthritisAnkylosing SpondylitisBursitis
CYLTEZO
ADALIMUMAB-ADBM
3 shared
Boehringer Ingelheim
Shared indications:
Rheumatoid ArthritisJuvenile Idiopathic ArthritisAnkylosing Spondylitis
DIFLUNISAL
DIFLUNISAL
3 shared
Teva
Shared indications:
PainOsteoarthritisRheumatoid Arthritis
ELYXYB
CELECOXIB
3 shared
SCILEX PHARMS
Shared indications:
OsteoarthritisRheumatoid ArthritisAnkylosing Spondylitis
HADLIMA
ADALIMUMAB-BWWD
3 shared
SAMSUNG BIOEPIS CO LTD
Shared indications:
Rheumatoid ArthritisJuvenile Idiopathic ArthritisAnkylosing Spondylitis
HULIO
ADALIMUMAB-FKJP
3 shared
Viatris
Shared indications:
Rheumatoid ArthritisJuvenile Idiopathic ArthritisAnkylosing Spondylitis
HUMIRA
ADALIMUMAB
3 shared
AbbVie
Shared indications:
Rheumatoid ArthritisAnkylosing SpondylitisJuvenile Idiopathic Arthritis
HYRIMOZ
ADALIMUMAB-ADAZ
3 shared
Novartis
Shared indications:
Rheumatoid ArthritisJuvenile Idiopathic ArthritisAnkylosing Spondylitis
IDACIO
ADALIMUMAB-AACF
3 shared
Fresenius Kabi
Shared indications:
Rheumatoid ArthritisJuvenile Idiopathic ArthritisAnkylosing Spondylitis
SIMLANDI
ADALIMUMAB-RYVK
3 shared
ALVOTECH USA INC
Shared indications:
Rheumatoid ArthritisJuvenile Idiopathic ArthritisAnkylosing Spondylitis
SIMPONI ARIA
GOLIMUMAB
3 shared
Johnson & Johnson
Shared indications:
Rheumatoid ArthritisAnkylosing SpondylitisJuvenile Idiopathic Arthritis
SULINDAC
SULINDAC
3 shared
WATSON LABS
Shared indications:
OsteoarthritisRheumatoid ArthritisAnkylosing Spondylitis
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

EC-NAPROSYN FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

Naproxen tablets and naproxen sodium tablets are indicated for: the relief of the signs and symptoms of: • rheumatoid arthritis • osteoarthritis • ankylosing spondylitis • Polyarticular Juvenile Idiopathic Arthritis Naproxen tablets and naproxen sodium tablets are also indicated for: the relief of signs and symptoms of: • tendonitis • bursitis • acute gout the management of: • pain • primary dysmenorrhea Naproxen tablets and naproxen sodium tablets are non-steroidal anti-inflammatory drugs indicated for: the relief of the signs and symptoms of: • rheumatoid arthritis • osteoarthritis • ankylos...

⚠️ BOXED WARNING

WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS Cardiovascular Thrombotic Events • Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occu...

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.